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ure, and the need for careful handling of the SV to mini-
mize vessel damage is generally accepted.3 However, con-
ventional SV harvesting techniques that involve the
removal of the perivascular tissue and distension still result
in significant vessel wall damage.4
A novel “no-touch” technique has been recently
described in which the SV is harvested with a pedicle of
surrounding tissue (Fig 1).5 Reduced venospasm has been
observed with this technique, hence avoiding the need for
mechanical distension. A prospective study with this tech-
nique in 52 patients who underwent CABG has shown
improved early patency rates of 95% at 18-month follow-
up examination.6 Previous studies into the mechanisms of
its success have shown that endothelial integrity and lume-
nal nitric oxide synthase (NOS) are better preserved with
this no-touch technique,7,8 which suggests that the nitric
oxide (NO) pathway plays an important role.
NO is a potent vasorelaxant that is synthesised from 
L-arginine by the enzyme NOS.9 Other properties of NO
that may be beneficial to vein graft patency include its abil-
ity to inhibit platelet aggregation and activation, leucocyte
adhesion, and vascular smooth muscle cell proliferation.
Three isoforms of NOS have been identified: neuronal
The saphenous vein (SV) is the most commonly used
conduit in coronary artery bypass graft surgery (CABG).
However, graft occlusion with its clinical sequelae remains
an unresolved problem. During the 1st year after bypass
graft surgery, as much as 30% of these grafts occlude.1
Continued attrition rates of 1% to 2% per year occur in the
next 5 years, increasing to 4% subsequently. By 10 years,
only 50% of vein grafts remain patent.1,2 Damage to the
SV during surgery is recognized to contribute to graft fail-
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Objective: The use of the saphenous vein in coronary artery bypass graft surgery is associated with high 1-year occlu-
sion rates of as much as 30%. A new “no-touch” technique of saphenous vein harvesting in which the vein is harvested
with a pedicle of surrounding tissue and not distended may result in improved early patency rates. We hypothesize that
nitric oxide synthase is better preserved with the no-touch technique, and the aim of this study was the investigation
of whether nitric oxide synthase distribution and quantity in saphenous veins harvested with the no-touch technique
differ from those veins harvested with the conventional technique. The separate contribution of perivascular tissue
removal and distension to alterations in nitric oxide synthase was also studied.
Methods: Segments of 10 saphenous veins were harvested from 10 patients who underwent coronary artery bypass graft-
ing surgery with the no-touch and conventional techniques. Samples were also taken from segments that were stripped
of surrounding tissue but not distended. Nitric oxide synthase distribution was studied with reduced nicotinamide ade-
nine dinucleotide phosphate–diaphorase histochemistry, and staining was quantified with image analysis.
Immunohistochemistry was used for the identification of specific nitric oxide synthase isoforms, and immunomarkers
were used for the identification of associated cell types.
Results: Nitric oxide synthase content was higher in no-touch vessels as compared with conventionally harvested vessels
(35.5%; P < .05, with analysis of variance). This content was associated with endothelial nitric oxide synthase on the
lumen while all three isoforms were present in the media. In the intact adventitia of no-touch vessels, all three isoforms
of nitric oxide synthase were also present, associated with microvessels and perivascular nerves. Perivascular tissue strip-
ping and venous distension both contribute to the reduced nitric oxide synthase in conventionally harvested veins.
Conclusion: The new no-touch technique of saphenous vein harvesting preserves nitric oxide synthase, which suggests
that improved nitric oxide availability may be an important mechanism in the success of this technique. (J Vasc Surg
2002;35:356-62.)
NOS (NOS I), inducible NOS (NOS II), and endothelial
NOS (NOS III). In the cardiovascular system, NOS is
known to be expressed by endothelial cells, vascular
smooth muscle cells, perivascular nerves, and platelets.9,10
We hypothesize that the NO pathway contributes to
the success of this technique and that NOS is better pre-
served in vein grafts harvested with this method. The aim
of this study was to investigate the distribution of NOS in
the media and adventitia of vessels harvested with the no-
touch and conventional techniques and to identify the
specific NOS isoenzymes involved. In addition, separate
segments of SV were used to investigate the individual
contribution of stripping and distension.
METHODS
After local ethics committee approval and patient
informed consent, SVs were harvested from 10 patients
who underwent CABG at the Orebro Medical Centre
Hospital, Sweden. In each patient, a segment of the SV
was harvested with the no-touch technique with a pedicle
of surrounding tissue, as described previously,5 while the
adjacent sections were stripped of surrounding tissue and
adventitia (conventional harvesting). Samples from each
segment then were taken to represent no-touch and con-
trol SV, respectively. The stripped SV segment then was
distended with saline solution at 300 mm Hg for 1 minute
with a syringe connected to a manometer, and samples
taken to represent conventionally harvested SV. The sam-
ples were frozen immediately in dry CO2 and stored at
–70°C.
Transverse sections of 10 µm were cryostat cut at
–25°C and thaw-mounted onto polylysine-coated micro-
scope slides and stored at –70°C until transfer to the Royal
Free Hospital for laboratory analyses. The slides were
coded to allow blind analyses.
Reduced nicotinamide adenine dinucleotide phos-
phate–diaphorase histochemistry. Reduced nicoti-
namide adenine dinucleotide phosphate (NADPH)–
diaphorase histochemistry was used to localize NOS on
tissue sections as previously described.11 Briefly, slide-
mounted sections were fixed in 3% paraformaldehyde in
0.01 mmol/L phosphate buffered saline solution (PBS)
buffer at 4°C for 30 minutes. The sections then were
rinsed in PBS, dried in cold air, and incubated with 1
mg/mL NADPH (Sigma Aldrich Co Ltd, Dorset, United
Kingdom) and 0.1 mg/mL nitroblue tetrazolium (Sigma
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Aldrich) in PBS buffer containing 0.2% Triton X-100
(Sigma), at 37°C for 1 hour. Negative controls were incu-
bated in the absence of NADPH. The reaction was
stopped with the removal of the incubation solution and
the rinsing of the sections in running tap water for 5 min-
utes. The sections then were stained with 0.1% eosin for 3
minutes and prepared for microscopic examination.
Immunohistochemistry. NOS isoforms were studied
with rabbit polyclonal anti-NOS antibodies (Santa Cruz
Biotechnology, Autogen Bioclear Ltd, Calne, UK) to
localize NOS I, NOS II, and NOS III. Monoclonal anti-
bodies to platelet-endothelial cell adhesion molecule-1
(CD31; DAKO Ltd, Denmark) and anti-neurofilament
(NF200; DAKO Ltd) were used for the identification of
endothelial cells and nerves and for the confirmation of
localization of NOS immunostaining.
Immunohistochemistry was performed with the
avidin-biotin-complex (ABC) peroxidase method for all
the previous antibodies. NOS isoforms were also studied
with the ABC alkaline phosphatase method. Briefly, for
the ABC peroxidase method, the sections were allowed to
equilibrate to room temperature, were fixed in acetone at
–20°C for 20 minutes, and were rinsed in PBS.
Endogenous peroxidase activity was inhibited with the
immersion in 0.5% hydrogen peroxide in methanol for 10
minutes and rinsing in PBS. The sections then were incu-
bated in 5% normal goat serum in PBS at room tempera-
ture for 20 minutes to block nonspecific staining. After the
removal of the blocking serum, the sections were incu-
bated in primary antibody diluted (NOS I, NOS II, and
NOS III, 1:400; CD31, 1:2000, NF200, 1:200) in PBS
for 1 hour at room temperature. After incubation, the sec-
tions were rinsed in PBS and incubated with biotinylated
secondary goat antibody for 30 minutes, followed by incu-
bation in streptavidin/biotinylated horseradish peroxidase
for 30 minutes (DAKO Ltd). Peroxidase activity was
revealed with diaminobenzidine as the chromagen.
For the ABC alkaline phosphatase method, the sec-
tions were fixed in acetone and then incubated in 1% nor-
mal horse serum for 20 minutes. Primary antibodies to
NOS I, NOS II, and NOS III diluted 1:200 in 1% normal
horse serum then were added for 1 hour at room temper-
ature. After rinsing in PBS, biotinylated universal sec-
ondary antibody was added for 30 minutes, followed 
by incubation in avidin and biotinylated alkaline phos-
phatase H solution for 30 minutes (Vector Laboratories,
Fig 1. Example of no-touch and conventional saphenous vein segments. Photograph of saphenous vein prepared with conventional and
no-touch techniques. No-touch segment (left) is surrounded with pedicle of tissue and is not distended, and conventionally prepared
segment (right) is stripped of this cushion of tissue and distended with saline solution. Bar = 2.5 cm.
Peterborough, United Kingdom). After the rinsing of the
sections in water, alkaline phosphatase activity was
revealed with incubation in Vector red alkaline phos-
phatase substrate for 20 minutes (Vector Laboratories).
Sections were lightly counterstained with Mayer’s
hematoxylin, prepared for microscopic examination, visu-
alized, and photographed with an Olympus BX 50 micro-
scope (Olympus Optical, London, UK). Vector red
staining was also visualized with fluorescence on a Zeiss
Axioplan microscope (Zeiss Ltd, Huntingdon, UK) and
photographed where appropriate.
Quantification of NADPH–diaphorase staining.
NADPH-diaphorase staining of whole sections represent-
ing “total tissue NOS” was quantified to assess the relative
amount of NOS present in the different vein segments.
Quantification was performed with a Zeiss KS400 image
analysis system (Zeiss Ltd, Huntingdon, UK). Here,
hematoxylin-stained transverse vein sections were cap-
tured at ×100 magnification with a ProgRes 3012 camera
(Imaging Associates, Thame, UK) attached to a Zeiss
Axioplan microscope. Digitized images of whole sections
were enhanced and segmented so that the internal (lume-
nal) and external (outer adventitia) edges were identified,
and a binary image was produced to represent the total tis-
sue area of each vein section analyzed. Next, blue
(NADPH-diaphorase) staining regions of each section
were enhanced and segmented to form a second binary
image. NADPH-diaphorase staining then was expressed as
a percentage of total tissue area for each section.
Three sections of each SV segment (conventional,
control, and no-touch) were analyzed from all 10 patients.
All the samples were performed in a blinded fashion. The
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data from each segment were presented as mean ± stan-
dard error of the mean percentage staining relative to the
no-touch sections from the same vein.
Statistical analysis. Analysis of variance and
Bonferroni adjustment multiple comparison tests were per-
formed with GraphPad Prism version 3.02 for Windows
(GraphPad Software, San Diego, Calif). Statistical signifi-
cance was inferred at P values of less than .05.
RESULTS
Patient demographics. The mean age of the 10
patients studied was 66 years (range, 57 to 81 years).
There were two female patients. Three of the patients
were smokers, and two had diabetes. All the patients were
taking aspirin, nine were on β-blocker and antihyperten-
sive therapy, and eight were taking lipid-lowering medica-
tion.
NADPH–diaphorase histochemistry. On the lume-
nal aspect of SV sections, NADPH-diaphorase staining to
identify NOS was almost continuous on the no-touch
vessels as compared with the conventional and control
vessels in which staining was patchy (Fig 2). This pattern
of staining was similar to that of positive CD31
immunoreactivity on adjacent sections. This pattern is in
keeping with the increased endothelial denudation of
conventionally harvested vessels, as previously described,8
which suggests that the endothelial cells are the lumenal
source of NOS.
In the media, NADPH-diaphorase staining was also
greatest in the sections of the no-touch vessels. This stain-
ing was reduced to some degree in the control (nondis-
tended) sections, with a further reduction seen in the
conventionally harvested (distended) sections (Fig 3). In
the intact adventitia of the no-touch vessels, NADPH
Fig 2. Lumenal NADPH–diaphorase staining on conventional
and no-touch vein sections. Nitric oxide synthase was identified on
conventional and no-touch vein segments with NADPH–
diaphorase histochemistry in which blue staining identifies puta-
tive nitric oxide synthase. Staining was almost continuous on
lumen of no-touch sections (B) but patchy on conventional sec-
tions (A). Staining was found to be associated with lumenal
endothelium with CD31 positive immunostaining. Arrows indi-
cate vessel lumen, which is collapsed. Bar = 100 µm.
Fig 3. Tissue NADPH–diaphorase staining: medial staining of
conventional, no-touch, and control vein segments. Sections of
conventional (A) and no-touch (B) saphenous vein were used to
identify tissue nitric oxide synthase with NADPH–diaphorase his-
tochemistry. Segments of vein that were prepared conventionally
(stripped of adventitia) but not distended (C) were also examined
(control). Such sections were used for assessment of tissue nitric
oxide synthase with computer-assisted image analysis (see Fig 5).
Apart from staining of endothelium, there was dense staining of
smooth muscle cells of tunica media. Bar = 200 µm.
staining was also associated with CD31-positive vasa vaso-
rum/microvessels and NF200-positive perivascular nerves
(Fig 4).
Image analysis results showed that tissue NADPH-
diaphorase staining was reduced by 19.5% in the control
(nondistended) sections as compared with the no-touch
sections, with the reduction in the conventionally har-
vested (distended) vessels being even greater at 35.5% as
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compared with the no-touch sections (P < .05, with analy-
sis of variance with Bonferroni adjustment multiple com-
parison test; Figs 3 and 5).
Nitric oxide synthase immunohistochemistry.
Positive NOS III immunostaining was identified on the
lumenal aspect of the vessels that was almost continuous
on the no-touch and control sections but that was reduced
and patchy on the conventional sections (Fig 6). All three
isoforms were identified in the media, which contributed
to the positive NADPH-diaphorase staining. In the intact
adventitia of the no-touch vessels, abundant NOS III–
positive staining was associated with microvessels, and this
colocalized with positive CD31 staining. These microves-
sels also stained positive for NOS II. NOS I immuno-
staining was associated with adventitial perivascular nerves
(not shown).
DISCUSSION
Despite the introduction of various surgical modifica-
tions and pharmacologic interventions, vein graft patency
rates in CABG remain relatively poor and represent a sig-
nificant clinical problem. During the 1st postoperative
month, thrombotic occlusion is the main cause of graft
failure. Endothelial cell loss and medial damage that
occur during surgery4,12 and the hemodynamic changes
in the arterialized vein contribute to this prothrombotic
state.13 Between 1 month and 1 year after vein graft
surgery, intimal hyperplasia is the major disease process in
vein grafts. This accumulation of vascular smooth muscle
cells and extracellular matrix in the intima occurs in
response to the increase in vessel wall pressure and
Fig 4. NADPH–diaphorase staining in adventitia of no-touch
vein: associated with vasa vasorum and nerves. There were
regions of NADPH–diaphorase staining in adventitia of no-touch
vein segments (B and D) that were absent in conventional seg-
ments in which adventitia had been removed. This staining was
associated with microvascular endothelium (positive CD31
immunostaining) and perivascular nerves (N, positive NF2000
immunostaining) identified on adjacent sections (A and C). Bar
= 50 µm.
Fig 5. Quantitative assessment of reduced NADPH–diaphorase
staining of saphenous vein (SV) sections. Regions of blue
NADPH–diaphorase staining were identified on sections of con-
ventional, control (nondistended), and no-touch saphenous vein
and expressed as percent total tissue area, relative to no-touch sec-
tions. *Conventional versus control, P < .05; conventional versus
no-touch, P < .01.
Fig 6. Immunohistochemical identification of nitric oxide syn-
thase III on lumenal endothelium of conventional and no-touch
vein sections. Nitric oxide synthase III was localized on lumenal
endothelium of no-touch vein sections with immunohistochem-
istry in which positive immunoreactivity shown with red fluores-
cence is continuous in no-touch vessels (A) and patchy in
conventional vessels (C). Endothelial integrity is shown with
hematoxylin counterstaining (B and D). Bar = 250 µm.
reduced shear stress.14 Other contributing factors are
thought to be vein wall ischemia as the result of loss of
vasa vasorum blood supply15 and the translocation and
transformation of adventitial fibroblasts to myofibroblasts
in the intima.16 Intimal hyperplasia results in graft
stenoses and initiates atheroma development,17 which is
the main cause of graft failure after the 1st year. The
accelerated atherosclerotic process seen in vein grafts is
similar to that described in chronic transplant rejection.18
The chronic endothelial damage and chronic dysfunction
associated with vein graft surgery, with a possible
immunologic component, have been suggested to con-
tribute to late graft failure.19
The new no-touch technique has led to improved
early patency rates at 18 months, when thrombosis, inti-
mal hyperplasia, and early atherosclerotic change may
have resulted in graft failure. Other no-touch techniques
that have been described previously only reduce direct
handling of the vein to various degrees during harvesting
and anastomosis. In this no-touch technique, the vein is
not manipulated directly but is handled via the intact cuff
of surrounding tissue during both harvesting and anasto-
mosis. In addition, most other no-touch techniques con-
tinue to use mechanical distension to overcome
venospasm, whereas no venospasm occurs with the new
no-touch technique, thus abolishing the need for disten-
sion. Surgical trauma therefore is minimized, and
endothelial, medial, and adventitial damage is markedly
reduced. Preserved lumenal endothelial integrity in veins
harvested with the no-touch technique has been reported
with electron microscopy7 and has been confirmed with
immunohistochemical studies.8 Because endothelial cell
loss is a strong prothrombotic stimulant,20 maintaining
the integrity of the endothelium would reduce the inci-
dence of early graft occlusion resulting from thromboses.
With the harvesting of the SV with a pedicle of tissue,
adventitial damage is prevented, which may reduce the
stimulus for adventitial fibroblast translocation and trans-
formation that contribute to intimal hyperplasia. In addi-
tion, vasa vasorum located in the adventitia are also
preserved, reducing vein wall ischemia, which may in turn
attenuate processes contributing to later vein graft occlu-
sion. The preserved vasa vasorum may also be an impor-
tant source of endothelial cells in the process of lumenal
reendothelialization.21
The surrounding cuff of tissue provides extra mechan-
ical support to the vein, which is of technical advantage
during surgery. In addition, it may confer hemodynamic
benefits after implantation with the reduction of vein wall
pressures and the provision of support to the arterialized
vein. This may reduce early thrombotic occlusions and
later medial thickening in a similar manner to the benefi-
cial effects described after external stenting of arteriove-
nous grafts.22,23
These results showed alterations in NOS distribution
in SV harvested with the no-touch technique as compared
with those in conventionally harvested SV. In addition to
the preservation of NOS associated with lumenal endothe-
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lial cells, NOS in the media and adventitia of no-touch
vessels was also preserved. In the adventitia, NOS sources
were identified that were associated with microvessels and
perivascular nerves. NOS levels were reduced with the
removal of the surrounding tissue from the SV and with
distension, which suggests that both of these procedures
contribute to the reduction in NOS seen in conventionally
harvested vessels. Distension appears to have a greater
effect on lumenal endothelial and medial NOS, and
removal of perivascular tissue eliminates important adven-
titial NOS sources. This preservation of NOS sources sug-
gests that NO availability, which is usually reduced with
conventional surgical preparation,24 may be improved
with the no-touch technique and that the NO pathway
contributes to the success of SV harvested with this
method.
During surgery and in the immediate postoperative
period, venospasm is often encountered, and NO donors
have been shown to reduce this via their vasodilator
action.25 Preservation of adequate endogenous NO may
provide protection against venospasm; indeed, no signifi-
cant venospasm occurs during surgery with the no-touch
technique, abolishing the need for distension and resultant
vascular damage. This protective mechanism may be main-
tained during the early postoperative period and may
counteract any effects of endogenous vasoconstrictors to
which the vein graft is highly sensitive.26-28
NO is also an important inhibitor of platelet adhesion
and activation,20 and this thromboresistant property
would be beneficial in reducing early thrombotic graft
occlusions. There is also evidence that NO stimulates
endothelial cell migration and proliferation,29,30 which
may lead to more rapid reendothelialization, which has
been shown to take as long as 30 days.31 This would
reduce the period during which the vein graft is vulnera-
ble to thromboses.
In late graft failure, NO may play a role in the reduc-
tion of intimal hyperplasia via its ability to inhibit smooth
muscle cell migration and proliferation.32,33 Inhibition of
intimal hyperplasia, together with protective effects on
endothelial cells and against chronic damage, will also
reduce subsequent atheroma development.
All three NOS isoforms were identified in the media of
SV grafts, where NO production would modulate vessel
tone. NOS I, II, and III expression in vascular smooth
muscle cells has been previously reported34-37 and has
been thought to be particularly important after vascular
injury in which NOS III–derived NO may be reduced as
the result of endothelial cell injury.
In no-touch vessels, NOS I was abundant in adventi-
tial nerves, NOS II was found in adventitial vasa vasorum,
and NOS III was associated with endothelial cells lining
both the vessel lumen and microvessels within the adven-
titia. The potentially beneficial involvement of all three
isoforms of NOS supports data from studies that show
that all isoforms are vasculoprotective. NOS I, produced
by perivascular nerves, has been shown to modulate vas-
cular tone of cerebral arteries38 and may play a similar role
in the SV, causing vasodilation. NOS III reduces intimal
hyperplasia in NOS III knockout39 and NOS III trans-
genic mice studies.40 Similar studies, with the carotid
artery ligation model in NOS II knockout mice, have
described suppressed constrictive remodeling with this iso-
form.39 The presence of these isoforms in no-touch vessels
may reduce intermediate and late occlusions via attenua-
tion of intimal hyperplasia and constrictive vascular
remodeling.
In conclusion, NOS sources are maintained with the
new no-touch technique of SV harvesting. The preserva-
tion of the NO-producing capacity of veins harvested with
this method is likely to represent an important mechanism
contributing to the improved early patency rate reported
with this technique. The contribution of this mechanism
to long-term graft patency remains to be established with
ongoing clinical follow-up studies. 
We thank Dr John Muddle for his help with the image
analysis. 
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